Idiopathic Thrombocytopenic Purpura Therapeutics Market Size was valued at USD 0.6 Billion in 2023. The idiopathic thrombocytopenic purpura therapeutics market industry is projected to grow from USD 0.7 Billion in 2024 to USD 0.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.30% during the forecast period (2024 - 2032). Major market drivers driving idiopathic thrombocytopenic purpura therapeutics market revenue growth include the aging population, rising prevalence of ITP, chemical exposure, viral infections, and genetic predisposition.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The need for idiopathic thrombocytopenic purpura therapy is expected to increase in different parts of the world. The increasing incidence of acute and chronic immunological thrombocytopenia throughout the forecast period is expected to rise worldwide adoption of treatment by keeping patient healthcare professionals aware of the increasing incidence of rare diseases has a positive impact on Enic Purpura Therapeutics market CAGR growth. NGOs involved in educating the public about immunodeficiency virus (ITP) and other blood abnormalities are Platelet Disorders Aid Society and the Immune Thrombocytopenia Support Society. It is expected that these NGO programs will increase the demand for pharmaceuticals in the idiopathic thrombocytopenic purpura treatment market.
Furthermore, idiopathic thrombocytopenic purpura (ITP) is one of many health problems that can now be diagnosed more accurately, rapidly, and accurately thanks to advances in diagnostic technologies (NGS) and polymer chain reaction (PCR). Therefore, there are two examples of molecular diagnostic methods that have been highly effective in revealing the fundamental causes of ITP. By identifying genetic markers associated with immune regulation and platelet damage, this technology provides important insights into the pathophysiology of the disease and potential therapeutic targets. Furthermore, point-of-care testing platforms make it possible to quickly and easily determine platelet counts, which helps with prompt therapies in situations of acute ITP. The use of advanced diagnostic technology has greatly improved our capacity to identify and treat ITP. By enabling early intervention, individualized treatment options, and accurate monitoring of disease response, continued progress in this field holds the prospect of further improving patient outcomes. Thus, driving the idiopathic thrombocytopenic purpura therapeutics market revenue.
The Idiopathic Thrombocytopenic Purpura Therapeutics Market segmentation, based on disease type, includes Acute ITP, Chronic, and Others. In 2023, the acute ITP segment dominated the market. Acute ITP is a type of illness that usually affects children and is self-limiting. It is typified by an abrupt start of low platelet counts, and most instances go away after six months. Supportive care and vigilant observation are frequently the main goals of the management of acute ITP. In comparison to chronic ITP, the market for idiopathic thrombocytopenic purpura therapeutics may be smaller due to its self-resolving nature.
The Idiopathic Thrombocytopenic Purpura Therapeutics Market segmentation, based on product, includes Corticosteroids, Intravenous Immunoglobulin (IVIg), Anti-D Immunoglobulins, TPO-RA, and Others. The corticosteroids category generated the most income in 2023. Corticosteroids are highly utilized since they are typically used as the initial treatment for people with idiopathic thrombocytopenic purpura. Furthermore, the decreased cost of these drugs and generally positive responses from patients have helped to increase their adoption for this segment of the market, especially in developing and emerging markets.
Figure 1: Idiopathic Thrombocytopenic Purpura Therapeutics Market, by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American idiopathic thrombocytopenic purpura therapeutics market area will dominate this market. Disease spread, increasing awareness and idiopathic thrombocytopenic purpura diagnosis, advanced treatment modalities influenced the growth of the idiopathic thrombocytopenic purpura treatment market in North America as well due to the adoption of new treatments and continuous research and development, including active clinical trial activities -The market is growing due to efforts
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe idiopathic thrombocytopenic purpura therapeutics market accounts for the second-largest market share. The idiopathic thrombocytopenic purpura therapeutics market is expected to grow in this sector due to the presence of several significant competitors, increasing R&D efforts, and growing ITP prevalence. Government initiatives and spending on healthcare infrastructure are expected to increase, which will help the market for idiopathic thrombocytopenic purpura therapeutics in Europe. Further, the German idiopathic thrombocytopenic purpura therapeutics market held the largest market share, and the UK idiopathic thrombocytopenic purpura therapeutics market was the fastest growing market in the European region.
The Asia-Pacific Idiopathic Thrombocytopenic Purpura Therapeutics Market is expected to grow at the fastest CAGR from 2024 to 2032. The increasing idiopathic thrombocytopenic purpura therapeutics market penetration rates in developing countries like South Korea, China, Taiwan, and India, as well as the wealth of untapped commercial opportunities in these areas, are some of the reasons behind this. Furthermore, the availability of government efforts in Australia and Japan that are expected to be favorable is expected to drive regional idiopathic thrombocytopenic purpura therapeutics market expansion. Moreover, China’s idiopathic thrombocytopenic purpura therapeutics market held the largest market share, and the Indian idiopathic thrombocytopenic purpura therapeutics market was the fastest-growing market in the Asia-Pacific region.
Idiopathic Thrombocytopenic Purpura Therapeutics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the idiopathic thrombocytopenic purpura therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, idiopathic thrombocytopenic purpura therapeutics industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global idiopathic thrombocytopenic purpura therapeutics industry to benefit clients and increase the market sector. In recent years, the idiopathic thrombocytopenic purpura therapeutics industry has offered some of the most significant advantages to medicine. Major players in the idiopathic thrombocytopenic purpura therapeutics market are attempting to increase market demand by investing in research and development operations, including GSK plc., Amgen Inc., F. Hoffmann-La Roche Ltd, Shangxian Minimal Invassive Inc., Grifols, S.A., JINSHAN Science & Technology (Group) Co., Ltd., Medtronic, INTROMEDIC, FUJIFILM Holdings Corporation, and Olympus Corporation.
Biotechnology business Amgen Inc. discovers, develops, and distributes breakthrough human drugs to treat patients with life-threatening diseases and develops breakthrough drugs to treat diseases related to cardiovascular, hematological and cancer, inflammation, bone health, neurological diseases and nephrology, examines the challenges faced, and understands the principles of human biology Amgen supplies its products primarily to large pharmaceutical distributors in the United States. Amgen Inc. announced in April 2021 that the U.S. Riabni has been approved by the FDA for the treatment of adult patients with idiopathic thrombocytopenic purpura, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma
GSK plc (GSK) is a pharmaceutical company specializing in the research, development, manufacture and commercialization of vaccines, specialty drugs and generic drugs for HIV, respiratory, cancer, immuno-inflammatory, central nervous system (CNS), metabolic, cardiovascular, In addition to products for urogenital disorders, and dermatology and rare diseases, the company sells products for gastrointestinal disorders, nutrition, skin care, pain management and dental health The European Medicines Agency (EMA) will release GSK's Zemperly drug in July 2021 to treat adult patients with advanced or recurrent cervical cancer.
Key companies in the idiopathic thrombocytopenic purpura therapeutics market include
Idiopathic Thrombocytopenic Purpura Therapeutics Industry Developments
December 2022: Amgen Inc. purchased Horizon Therapeutics plc. Amgen Inc.'s distinctive medicines portfolio is anticipated to be strengthened by the acquisition. The partnership also simplifies the utilization of Amgen Inc.'s global reach and two decades of experience in nephrology and inflammation.
August 2021: Promacta, a medication manufactured by Novartis AG, was approved by the US FDA to treat persistent ITP in children. Adults with the same ailment had previously been given approval to use the medication.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.6 Billion |
| Market Size 2024 | USD 0.7 Billion |
| Market Size 2032 | USD 0.98 Billion |
| Compound Annual Growth Rate (CAGR) | 5.30% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Product, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | GSK plc., Amgen Inc., F. Hoffmann-La Roche Ltd, Shangxian Minimal Invassive Inc., Grifols, S.A., JINSHAN Science & Technology (Group) Co., Ltd., Medtronic, INTROMEDIC, FUJIFILM Holdings Corporation, and Olympus Corporation. |
| Key Market Opportunities | · Increasing R&D efforts in preparation for the introduction of novel medications |
| Key Market Dynamics | · Rising idiopathic thrombocytopenic purpura prevalence · Growing demand for combination treatments |
Frequently Asked Questions (FAQ) :
The Idiopathic Thrombocytopenic Purpura Therapeutics Market size was valued at USD 0.6 Billion in 2023.
The global market is projected to grow at a CAGR of 5.30% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are GSK plc., Amgen Inc., F. Hoffmann-La Roche Ltd, Shangxian Minimal Invassive Inc., Grifols, S.A., JINSHAN Science & Technology (Group) Co., Ltd., Medtronic, INTROMEDIC, FUJIFILM Holdings Corporation, and Olympus Corporation.
The acute ITP category dominated the market in 2023.
The corticosteroids category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
